Gavi and Coare lying about the efficacy and safety of HPV vaccines
By Dr. G. Delépine, cancer surgeon and statistician
The Cochrane Collaboration was once the model of an organization whose rigorous macro-analyses objectively summarized the state of knowledge in medicine. Its conclusions frequently contradicted the lies propagated by Gavi and Bill Gates. The Bill Gates Foundation then made a "donation" of $1.15 million to the association [1], which subsequently expelled Peter Gøtzsche for being too critical[2]. Since this donation, Cochrane's publications have bowed to Gates' wishes, such as one of its latest macroanalyses claiming that "the HPV vaccine is very effective in preventing cervical cancer and has no serious side effects"[3].
The Gavi Foundation does not limit itself to telling enormous lies[4], proclaiming on France 24[5], Libération[6], Le Figaro [7], and through Luc Blanchot[8] that " the HPV vaccine has saved more than a million lives worldwide" without specifying its sources or how this figure was arrived at.
It is therefore necessary to reiterate the reality of this vaccine's disappointing results in the real world.
In 2025, there is absolutely no evidence that this vaccine has prevented a single case of cancer.
No randomized trials have demonstrated any reduction in the incidence of cervical cancer among those vaccinated; on the contrary, in the pivotal trials that led to their market approval, women vaccinated late in life suffered an increase in precancerous lesions. To claim otherwise, the reviewers excluded them from the analysis, thereby completely violating the principle of randomized trials and the honesty of their conclusion.
Nineteen years after its release, numerous publications by authors linked to the pharmaceutical industry or vaccination agencies continue to claim that vaccination prevents cancer. but examination of these publications shows that the data are not based on real-world observations of at-risk groups [9] but on unexposed or idealized groups[10] derived from simple estimates based on simulations biased[11] by false assumptions.
The unbelievable lie about saving 17 lives for every 1,000 vaccinated!
In its press release, Gavi claims that HPV vaccination could prevent 17.4 deaths per 1,000 girls vaccinated. This claim is completely inconsistent with official data.
Worldwide, average life expectancy is around 70 years, with an annual mortality rate for cervical cancer of close to 2/100,000 [12] [13] [14]. Over a lifetime, the risk of death from cervical cancer can therefore be estimated at 1.4 per 1,000 women [15], which is 12 times less than what Gavi claims can be prevented by the vaccine (17/1,000).
In Africa, the continent most affected by this cancer, the main causes of mortality are [16] malaria, HIV/AIDS, respiratory tract infections, diarrheal diseases, perinatal conditions, cardiovascular diseases, tuberculosis, ischemic heart disease, measles, and road traffic accidents. Only 20% of deaths are due to cancer[17], of which about 20% are due to cervical cancer[18] (representing 4% of overall mortality). In 2022, approximately 100,000 invasive cervical cancers were recorded and nearly 76,000 women died from the disease [19] in the 47 African states with a population of 700 million women, or 1/10,000 women. For an average lifespan of 60 years, lifetime mortality can be estimated at 6/1000, which is three times less than what Gavi claims can be prevented by the vaccine.
How could a vaccine, even if it were completely effective, prevent 3 to 12 times more deaths than the mortality rate of the cancer it is supposed to combat?
Gavi seems to be inspired by the principles of Joseph Goebbels (Adolf Hitler's propaganda minister): " The bigger the lie, the more people will believe it" and "A lie repeated a thousand times becomes the truth."
The misinformation spread by Gavi is perpetuated by the media, which continues to publish press releases from the pharmaceutical industry without ever verifying the accuracy of official data, thereby grossly violating the journalistic ethics summarized in their charter.
HPV vaccines have been unable to prevent cancer
In the absence of conclusive randomized trials, the estimated effect of these vaccines can be measured by the change in the incidence of cervical cancer described in the cancer registries of countries that have mandated vaccination. These registries are maintained by officials who are independent of the pharmaceutical industry.
All published data from these registries show that cytological screening has been followed everywhere by a 30% to 70% decline in the incidence of invasive cervical cancer. And since vaccination began, the overall incidence has stagnated and even often increased in the group of vaccinated women who have reached the age of cervical cancer.
In Australia, cytological screening introduced in 1991 was followed by a nearly 50% decline in incidence (from 13 in 1991 to 7 in 2006).
However, the introduction of school vaccinations at age 12–13 and catch-up vaccinations up to age 25[21] 19 years ago has not reduced the incidence among the general population. It has even increased in the control group of vaccinated women who have reached the age of cancer (over 25):
In the group of late vaccinees (who were between 13 and 25 years old at the time of Gardasil vaccination and 30-42 years old in 2023), the injection was followed by an even greater increase in incidence (50%).
This increase in incidence among vaccinated groups who have reached cancer age may partly explain the gradual decline in the rate of vaccination before the age of 15 observed in Australia since 2020. The increase in incidence in vaccinated groups is all the more surprising given that during this period, older women, who were not eligible for vaccination, saw their risk of cancer decrease significantly thanks to screening campaigns: -30% (5.6 to 4) for 60-64 year olds, -20% (6.5 to 5.1) for 65-69 year olds, and -28% (5.3 to 3.8) for 70-74 year olds.
In 2024, the Australian National Agency estimated the number of new cervical cancers at 1,030 (an increase of nearly 33% from the pre-vaccination figure) and its incidence at 7.1/100,000[22] (15% higher than in France, where vaccination rates are low). How can we believe in the imminent eradication of cancer that Gardasil advocates constantly promise in all the media[23]?
Great Britain introduced Gardasil vaccination in schools for girls in 2007. Eighteen years later, the incidence of cervical cancer has increased in the control group of vaccinated women (aged 25-34), while it continues to decline in women over 40 (unvaccinated).
This increase in incidence among vaccinated individuals casts serious doubt on the promise of imminent eradication of this disease trumpeted by vaccine advocates[24].
In Finland, organized screening for cervical cancer, which has been in place for over 30 years, has led to a 70-80% decrease in the age-adjusted incidence of this cancer, as well as a reduction in mortality. However, Gardasil's failure to prevent cancer has also been observed there.
In the most vaccinated group that has reached cancer age (25-34 years old), the incidence of cervical cancer has increased by more than 70% (from 4.5 to 8).
In Denmark
The vaccination of more than 85% of young girls was followed by an 8% increase in the incidence of cervical cancer, while it decreased by 8% in women over 40 (unvaccinated).
The ineffectiveness of Gardasil in preventing invasive cervical cancer has also been observed in Norway.
Furthermore, anal cancer is observed almost exclusively in passive homosexuals and immunocompromised individuals. Passive anal sex is the most significant causal factor and partly explains the consistently higher risk for women compared to heterosexual men (3 to 4 times higher risk), and the 60 to 90 times higher risk for passive male homosexuals, with an incidence of anal cancer of 95/100,000, peaking at 130/100,000 in those who are also HIV-positive. For a non-immunocompromised heterosexual male, the risk of anal cancer is virtually zero. Organ transplant patients taking immunosuppressive drugs suffer from an incidence of anal cancer five times higher than the general population, a rate close to that of heterosexuals infected with HIV.
In Canada
vaccination with Gardasil is also followed by an increase in the incidence of cervical cancer
This stabilization or increase in the incidence of invasive cancers in countries that have introduced widespread vaccination with Gardasil contrasts with the steady decline in the incidence of cervical cancer in France, where officials nevertheless constantly lament our low vaccination rate.
In our country, where vaccination rates are low, cervical cancer has become a rare disease, unlike in countries with high vaccination rates that our leaders cite as examples! And if we accept the new definition of eradication advocated by the WHO, we would have even eradicated it!
But it is true that for the cronies of Big Pharma and their shareholders, the only thing that matters is vaccinating everyone, regardless of the clinical results.
Gardasil is of no benefit to boys.
To double the market for Gardasil, vaccination has been promoted among boys under the pretext of preventing anal and throat cancers.
However, anal canal cancer is very rare in men in France, where it does not constitute a public health problem. In 2018, fewer than 400 cases were reported in men, compared to the burden of prostate cancer (59,885 new cases in 2023) and lung cancer (33,438 men in 2023).
Furthermore, it has not been proven that Gardasil can prevent this cancer.
National cancer registry data show that since the introduction of school vaccinations, there has been a greater increase in the incidence of anal cancer among vaccinated girls than among boys.
Gavi and Coare lying when they claim that vaccination with Gardasil is safe [25]
On Friday, October 27, 2023, at Saint-Dominique Middle School in Saint-Herblain, near Nantes, a 7th grader died after receiving the Gardasil vaccine during the large-scale HPV vaccination campaign in French middle schools initiated by President Macron. The Regional Health Agency was quick to assert that the vaccine was not responsible and rejected any malfunction in the organization of the vaccination campaign.
Yet no one can deny that this child, who was in perfect health before the injection, died as a result of the school vaccination. But, as usual, the courts did not question the state's responsibility in prescribing the vaccination, but only the scapegoat (the doctor), who is now under investigation for manslaughter.
This death following Gardasil injection is unfortunately not unusual.
In the US, according to the Vaccine Adverse Events Reporting System (VAERS), more than 400 deaths have been reported after Gardasil vaccination. [26].
These deaths are the reason for numerous complaints in the US[27] following Gardasil vaccination. It should be noted that, during the clinical trials that preceded market authorization, the mortality rate among vaccine recipients was 8.5/10,000, nearly double the rate among women aged 15-24 in the general population. However, this was considered a "coincidence" by the laboratories and the US Food and Drug Administration (FDA).
A critical review of these trials confirms the higher mortality rate among vaccinated women over the age of 25, whose mortality rate was 2.36 times higher than in the placebo group. "When all the deaths among mid-adult women enrolled in the three trials are pooled, a higher case fatality rate was observed among those who received HPV vaccine compared to those who received placebo." [28]
But the National Agency for Medicines Safety claims that Gardasil mortality spares the French (just as the agency responsible for nuclear protection claimed that the Chernobyl cloud spared France).
Vaccination with Gardasil exposes individuals to numerous other complications.
According to the National Vaccine Information Center, tens of thousands of complications have been reported following Gardasil vaccination. The list of possible adverse events is detailed in official CDC publications [29].
and publications from The National Network for Immunization[30].
Some very common complications are mild and temporary, such as pain during injection, edema, swelling, fever, cough, malaise, hives, lymphadenopathy, epigastric pain, nasopharyngitis, headache, or nausea, sometimes accompanied by diarrhea or vomiting.
Some are more severe, such as arthralgia, arthritis, immune hemolytic anemia, pancreatitis, hypothyroidism, syncope, contractures, respiratory infection, gastroenteritis, appendicitis, urinary tract infection, postural orthostatic syndrome, thrombocytopenic purpura, lupus erythematosus, myalgia, premature ovarian failure, infertility, etc.
The most serious complications, fortunately very rare, such as Guillain Barre syndrome, transverse myelitis, progressive encephalitis, pulmonary embolism, bronchospasm, or anaphylactic shock, can be life-threatening, which is unacceptable for a potentially preventive treatment for a disease that already benefits from highly effective and completely safe prevention (cytological screening).
According to figures from the US Gardasil package insert, North American women are 100 times more likely to suffer a serious event after vaccination with Gardasil than to develop cervical cancer. In particular, the risk of contracting an autoimmune disease linked to Gardasil, even if the vaccine were effective, is far greater than the risk of avoiding death from cervical cancer.
Are Gavi, Cochrane since its acquisition by Gates, the French Medicines Agency, and the mainstream media deliberately lying, unaware of the English in the American Gardasil package insert, or simply ignoring the CDC information that makes it inconvenient for them to claim that "Gardasil is safe"?
Doctors who vaccinate with Gardasil are liable to legal action
The indictment of the French doctor who injected the deadly Gardasil vaccine into the child in Nantes is likely to be repeated in the event of the next vaccine accident, as the European Court of Justice recently ruled that " doctors are solely responsible for the consequences of injections because they are free to administer them, advise against them, or refuse to do so."
The Court even specified that "the marketing authorization issued by the European Medicines Agency does not impose any obligation on doctors to prescribe and administer these vaccines to their patients."
Doctors and other practitioners who may administer Gardasil must therefore be particularly vigilant regarding the quality and completeness of the information provided to patients concerning the risks of vaccines and the steps to take in the event of suspected adverse reactions. Even during an official campaign organized at school, they may be held liable.
In addition to being ineffective and dangerous, Gardasil costs a fortune.
In France, the flu vaccine costs €6 to €11, the Sanofi COVID-19 vaccine costs €7.56, and the Infanrix Tetra® vaccine costs €14.63. One dose of Gardasil is sold at a price of €116.83, which is an all-time high for a vaccine. Depending on the age of the person being vaccinated, two or three doses may be recommended. Taking into account the necessary medical consultations, HPV vaccination for an adult costs €500 and for a teenager around €350.
The cost of manufacturing one dose of Gardasil is estimated at less than $1 in Chaevia Clendinen's well-documented study [31], which states that " the manufacturing costs of Gardasil sold to Gavi and developing countries range from $0.48 to $0.59 per dose."
Between 2006 and 2015, Merck earned nearly $14 billion from Gardasil sales, which then stabilized at $5-6 billion annually, reaching nearly $40 billion since its launch. According to some estimates, the Gardasil market is projected to be worth $46 billion by 2023. This colossal windfall strongly motivates Merck's shareholders to subsidize its propaganda and gives the company considerable resources to convince political leaders and their advisors to promote Gardasil.
In the US, with 76 million children vaccinated at an average cost of $420 for the three-dose series, saving one American life from cervical cancer would cost approximately $18.3 million. In comparison, the value of a human life, according to the National Vaccine Injury Compensation Program of the Department of Health and Human Services (HHS), is $250,000, the maximum amount that the government program awards in cases of vaccine-related death.
In France, vaccinating an age group would cost nearly €300 million. Assuming the unlikely scenario of absolute efficacy, this would prevent 1,000 deaths each year, representing a unit cost per life saved of €300,000, which completely contradicts the advertising campaign published by Santé Publique France in 2019.
At a time when our finances and hospitals are in such dire straits, considering spending such a large sum on Gardasil, given its unfavorable risk-benefit ratio, is utterly scandalous.
[1] https://regisliber.wordpress.com/2020/05/14/pourquoi-la-fondation-gates-a-t-elle-rachete-cochrane/
[2] Peter Gotzsche, the man at the center of the controversy
[3] Gabriela Galvin HPV vaccine: risk of cervical cancer falls, side effects minimal, according to extensive review Euronews 11/24/2025
[4] https://www.gavi.org/fr/actualites/media-room/vaccin-contre-cancer-col-uterus-sauve-plus-dun-million-vies
[5] https://www.france24.com/fr/sant%C3%A9/20251116-cancer-col-uterus-vaccin-hpv-papillomavirus-sauve-un-million-de-vies-dans-pays-faible-revenus-gavi-deces
[6] https://www.liberation.fr/societe/sante/papillomavirus-plus-dun-million-de-vies-sauvees-grace-a-la-vaccination-dans-les-pays-pauvres-20251117_MU7Y5ILXCRHOJAQNA6RUGSTAHU/
[7] https://sante.lefigaro.fr/cancer-du-col-de-l-uterus-une-nouvelle-etude-de-reference-confirme-l-interet-du-vaccin-anti-hpv-20251124
[8]Cervical cancer: the HPV vaccine has saved more than one million lives worldwide 11/18/2025
[9] Such as a recent Swedish article based on girls aged 10 to 30, whereas this cancer is usually only observed in women aged 25 and over.
[10] https://www.courrierinternational.com/article/vaccination-laustralie-reve-deradiquer-le-cancer-du-col-de-luterus
[11]https://www.gyneco-online.com/gynecologie/elimination-du-cancer-du-col-en-australie-une-projection-pour-lavenir
[12] Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005 Mar;16(3):481-8.
[13] Ferlay J, Bray F, Sankila R, Parkin DM. EUCAN: Cancer Incidence, Mortality and Prevalence in the European Union 1998. 1999. IARC CancerBase No.4, version 5.0. Lyon: IARC Press
[14] Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003 Feb;51(1 Pt 1):3-30
[15] https://www.donneesmondiales.com/esperance-vie.php#google_vignette
[16] Read more: https://globometer.com/mortalite-deces-afrique.php
[17] https://www.insee.fr/fr/statistiques/2385258
[18] J.-C. Kajimina Katumbayi Epidemiological and histopathological characteristics of 1,280 cervical cancers in Kinshasa https://www.sciencedirect.com/science/article/pii/S2468718921001860
[19] https://www.trtafrika.com/francais/article/18260132
[20]https://www.snj.fr/charte-dethique-professionnelle-des-journalistes/94
[21] https://www.health.gov.au/topics/immunisation/vaccines/human-papillomavirus-hpv-immunisation-service
[22] https://hpvcentre.net/statistics/reports/AUS_FS.pdf
[23]https://www.rtl.fr/actu/sante/papillomavirus-l-australie-en-passe-d-eradiquer-le-cancer-du-col-de-l-uterus-7794956907
[24] NHS England promises to eliminate cervical cancer by 2040 https://www.bbc.com/news/health-67420138
[25] Martínez-Lavín M, Amezcua-Guerra L. Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. Clin Rheumatol. 2017 Oct;36(10):2169-2178.
[26] https://vaers.hhs.gov/eSubDownload/index.jsp?fn=2025VAERSData.zip.
[27] https://www.wisnerbaum.com/prescription-drugs/gardasil-lawsuit/gardasil-deaths/
[28] https://pmc.ncbi.nlm.nih.gov/articles/PMC6494566/pdf/CD009069.pdf
[29] Human Papillomavirus (HPV) Vaccine Safety 6 3 2025 https://www.cdc.gov/vaccine-safety/vaccines/hpv.html
[30] https://immunizationinfo.com/gardasil-vaccine/
[31] Haevia Clendinen, Yapei Zhang, Rebecca N. Warburton, Donald W. Light, "Manufacturing costs of HPV vaccines for developing countries," Vaccine, volume 34, no. 48, November 21, 2016, pp. 5984-5989.
